Mucopolysaccharidosis Type I, Unique Structure of Accumulated Heparan Sulfate and IncreasedN-Sulfotransferase Activity in Mice Lacking α-l-iduronidase

ExtendedN-Sulfated Domains Reside at the Nonreducing End of Heparan Sulfate Chains

(2010) Gregory O. Staples et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Heparin cofactor II-thrombin complex and dermatan sulphate:chondroitin sulphate ratio are biomarkers of short- and long-term treatment effects in mucopolysaccharide diseases

(2010) Kia Jane Langford-Smith et al.   JOURNAL OF INHERITED METABOLIC DISEASE

Structure-Function Approach Identifies a COOH-Terminal Domain That Mediates Heparanase Signaling

(2009) L. Fux et al.   CANCER RESEARCH

Improved Metabolic Correction in Patients with Lysosomal Storage Disease Treated with Hematopoietic Stem Cell Transplant Compared with Enzyme Replacement Therapy

(2009) Robert F. Wynn et al.   JOURNAL OF PEDIATRICS

Evaluation of heparin cofactor II–thrombin complex as a biomarker on blood spots from mucopolysaccharidosis I, IIIA and IIIB mice

(2009) Kia Langford-Smith et al.   MOLECULAR GENETICS AND METABOLISM

A simplified and sensitive fluorescent method for disaccharide analysis of both heparan sulfate and chondroitin/dermatan sulfates from biological samples

(2008) J. A Deakin et al.   GLYCOBIOLOGY

Heparin/Heparan Sulfate Biosynthesis

(2008) Pernilla Carlsson et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Mucopolysaccharidosis I: Management and Treatment Guidelines

(2008) J. Muenzer et al.   PEDIATRICS

Heparan sulfate biosynthesis enzymes EXT1 and EXT2 affect NDST1 expression and heparan sulfate sulfation

(2008) J. Presto et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA